Useful Links
     Contact Us
       1503 E. Jefferson St
        Baltimore, MD 21231
       (410) 502-6057 
       (410) 502-1329   Fax




    Dr. Stephen Meltzer

    Professor of Medicine and Oncology
    Director, Early Detection Biomarkers Laboratory
    Division of Gastroenterology
    Department of Medicine
    The Johns Hopkins University School of Medicine

1503 E. Jefferson St, Rm 112
    Tel : (410) 502-6057
    Fax: (410) 502-1329


    B.A.,  1975, State University of NY, Binghamton, NY
    M.D., 1979, State University of NY, Buffalo, NY
    M. Music, University of Colorado, Boulder, CO


Dr. Stephen J. Meltzer is Professor of Medicine and Oncology at the Johns Hopkins University, Department of Medicine, Gastroenterology Division. He is also Director of the GI Early Detection Biomarkers Laboratory.

His research interests concern several areas: gastrointestinal cancer and precancer biomarker discovery, development and validation; genomics, epigenomics and bioinformatics; early detection of cancer; outcomes research in cancer and precancer; risk stratification prediction in cancer and precancer; Barrett's esophagus; inflammatory bowel disease-associated cancer; liver cancer; and gastric cancer.

After receiving his degree in Medicine at the State University of New York at Buffalo Medical School, Dr. Meltzer did his internal medicine internship at Tulane University in New Orleans, LA and his internal medicine residency at the University of Texas Medical Branch in Galveston, TX. He did a split GI fellowship at the University of Colorado, Denver, CO and at Lenox Hill Hospital, New York, NY. He did his molecular biology postdoctoral training, then became an Assistant Professor in Residence at UCLA Center for the Health Sciences in 1987. Prior to joining the faculty at Johns Hopkins in 2006, he was Professor of Medicine and Pharmacology, Founder and Head of the Aerodigestive Cancer/Biomarker Program at the University of Maryland at Baltimore School of Medicine. He is an Associate Editor of Cancer Research and a member of the editorial board of Esophagus as well as of Bioinformatics and Biology.

He has published 142 original scientific research articles in high-impact scientific journals. He also has authored 42 chapters, review articles, editorials, or letters to the editor; 1 book; and 130 abstracts. He has presented a plethora of invited lectures around the world, all concerning his principal field of esophageal and gastrointestinal cancer research. He has been the recipient of numerous prestigious national and international awards, including the Robert and Sally D. Funderburg Award in Gastric Cancer Biology, and is a member of the American Society for Clinical Investigation.


Models for tumor formation and lymph node metastasis in vivo.



1. Meltzer SJ, Korelitz BI. Budd-Chiari Syndrome. Gastroent. Obs. 1985; 4:3-8.

2. Haber CJ, Meltzer SJ, Present DH, Korelitz BI. The nature and course of pancreatitis caused by 6-mercaptopurine in the treatment of inflammatory bowel disease. Gastroenterol. 1986; 91:982-986.

3. Meltzer SJ, Goldberg MD. Recurrent pancreatitis caused by vegetable matter obstruction. Am. J. Gastro., 1986; 81:1091-1092.

4. Meltzer SJ, Goldberg MD, Meltzer RM, Claps F. Appendiceal obstruction by a toothpick removed at colonoscopy. Am. J. Gastro. 1986; 81:1107-1108.

5. Meltzer SJ, Rotterdam HZ, Korelitz BI. Kaposi’s sarcoma occurring in association with ulcerative colitis. Am. J. Gastro. 1987; 82:378-381.

6. Meltzer SJ, Ahnen DJ, Battifora H, Yokota J, Cline MJ. Proto-oncogene abnormalities in colon cancers and adenomatous polyps. Gastroenterol. 1987; 92:1174-1180.

7. Masuda H, Yokota J, Battifora H, Meltzer SJ, Cline MJ. Specificity of proto-oncogene amplification in human malignant diseases. Molec. Biol. Med. 1987; 4:213-227.

8. Meltzer SJ, Korelitz BI. Pancreatitis and duodenopancreatic reflux in Crohn's disease. J. Clin. Gastro. 1988; 10:555-558.

9. Mallet MK, Mane SM, Meltzer SJ, Needleman SW. C-myc amplification coexistent with activating c-N-ras point mutation in the biphenotypic leukemic cell line RED-3. Leukemia 1989; 3:511-515.

10. Present DH, Meltzer SJ, Krumholz MP, Wolke A, Korelitz BI. 6-mercaptopurine in the management of inflammatory bowel disease: short and long-term toxicity. Ann. Int. Med. 1989; 111:641-649.

11. Meltzer SJ, Zhou D, Weinstein WM. Tissue-specific expression of c-Ha-ras in premalignant gastrointestinal mucosae. Exper. Mol. Pathol. 1989; 51:264-274.

12. Meltzer SJ, Mane SM, Wood PK, Johnson LN, Needleman SW. Sequencing products of the polymerase chain reaction directly, without purification. Bio Techniques 1990; 8:142-148.

13. Meltzer SJ, Mane SM, Wood PK, Resau JH, Newkirk C, Terzakis JA, Korelitz BI, Weinstein WM, Needleman SW. Activation of c-Ki-ras in gastrointestinal dysplasias determined by direct sequencing of polymerase chain reaction products. Cancer Res. 1990; 50:3627-3630.

14. Mane SM, Meltzer SJ, Gutheil JV, Kapil V, Lee EJ, Schiffer CA, Needleman SW. Ras gene mutations in acute myeloid leukemia: Analysis by in vitro amplification and base sequence determination. Genes Chrom. Cancer 1990; 2:71-77.

15. McDaniel TK, Huang Y, Yin J, Needleman SW, Meltzer SJ. Direct labeling of PCR products using Klenow fragment. BioTechniques 1991; 11:164-166.

16. Meltzer SJ, Yin J, Huang Y, McDaniel TK, Newkirk C, Iseri O, Vogelstein B, Resau JH. Reduction to homozygosity involving p53 in esophageal cancers demonstrated by the polymerase chain reaction. Proc. Natl. Acad. Sci., USA 1991; 88:4976-4980.

17. McDaniel T, Carbone D, Takahashi T, Chumakov P, Chang EH, Pirollo KF, Yin J, Huang Y, Meltzer SJ. A polymorphism in intron 6 of p53 detected by digesting PCR products with Msp I. Nucleic Acids Res. 1991; 19:4796.

18. Boynton RF, Huang Y, Blount PL, Reid BJ, Raskind WH, Haggitt RC, Newkirk C, Resau JH, Yin J, McDaniel T, Meltzer SJ. Frequent loss of heterozygosity at the retinoblastoma locus in human esophageal cancers. Cancer Res. 1991; 51:5766-5769.

19. Greenwald BD, Harpaz N, Yin J, Huang Y, Tong Y, Brown VL, McDaniel T, Newkirk C, Resau JH, Meltzer SJ. Loss of heterozygosity affecting the p53, Rb, and MCC/APC tumor suppressor gene loci in dysplastic and cancerous ulcerative colitis. Cancer Res. 1992; 52:741-745.

20. Boynton RF, Blount PL, Yin J, Brown VL, Huang Y, Tong Y, McDaniel T, Newkirk C, Resau JH, Haggitt RC, Raskind WH, Reid BJ, Meltzer SJ. Loss of heterozygosity involving the APC and MCC genetic loci occurs in the majority of human esophageal cancers. Proc. Natl. Acad. Sci., USA 1992; 89:3385-3388.

21. D’Amico D, Carbone D, Johnson B, Meltzer SJ, Minna JD. Polymorphic sites within the MCC and APC loci reveal frequent loss of heterozygosity in human small cell lung cancer. Cancer Res. 1992; 52:1996-1999.

22. Greenwald BD, Huang Y, Baum R, Meltzer SJ. Barrett's carcinoma in a 25-year-old man with point mutation of the p53 tumor suppressor gene. Int. J. Oncol. 1992; 1:271-275.

23. Huang Y, Boynton RF, Blount PL, Silverstein RJ, Yin J, Tong Y, McDaniel TK, Newkirk C, Resau JH, Sridhara R, Reid BJ, Meltzer SJ. Loss of heterozygosity involves multiple tumor suppressor genes in human esophageal cancers. Cancer Res. 1992; 52:6525-6530.

24. Largey JS, Meltzer SJ, Yin J, Norris K, Sauk JJ, Archibald DW. Loss of heterozygosity of p53 in oral cancers demonstrated by the polymerase chain reaction. Cancer 1993; 71:1933-1937.

25. Blount PL, Meltzer SJ, Yin J, Huang Y, Krasna MJ, Reid BJ. Clonal ordering of 17p and 5q allelic losses in Barrett's dysplasia and adenocarcinoma. Proc. Natl. Acad. Sci., USA 1993; 90:3221-3225.

26. Huang Y, Meltzer SJ, Yin J, Tong Y, Chang EH, Srivastava S, McDaniel T, Boynton RF, Zou Z-Q. Altered mRNA and unique mutational profiles of p53 and Rb in human esophageal carcinomas. Cancer Res. 1993; 53:1889-1894.

27. Yin J, Harpaz N, Tong Y, Huang Y, Laurin J, Greenwald BD, Hontanosas M, Newkirk C, Meltzer SJ. p53 point mutations in dysplastic and cancerous ulcerative colitis lesions. Gastroenterol. 1993; 104:1633-1639.

28. Rosenblum-Vos LS, Meltzer SJ, Leanna-Cox J, Schwartz S. Cytogenetic studies in primary cultures of esophageal squamous cell carcinoma. Cancer Genet. Cytogenet. 1993; 70:127-131.

29. Rhyu M-G, Park W-S, Meltzer SJ. Microsatellite instability occurs frequently in human gastric carcinoma. Oncogene 1994; 9:29-32.

30. Largey JS, Meltzer SJ, Sauk JJ, Hebert CA, Archibald DW. Loss of heterozygosity involving the APC gene in oral squamous cell carcinomas. Oral Surg. Oral Med. Oral Pathol. 1994; 77:260-263.

31. Blount PL, Galipeau PC, Sanchez CA, Neshat K, Levine DS, Yin J, Suzuki H, Abraham JM, Meltzer SJ, Reid BJ. 17p allelic losses in diploid cells of patients with Barrett's esophagus who develop aneuploidy. Cancer Res. 1994; 54:2292-2295.

32. Rhyu M-G, Park W-S, Jung Y-J, Choi S-W, Meltzer SJ. Allelic deletions of APC/MCC and p53 are frequent late events in human gastric carcinogenesis. Gastroenterol. 1994; 106:1584-1588.

33. Meltzer SJ, Yin J, Manin B, Rhyu M-G, Cottrell J, Hudson E, Redd JL, Krasna MJ, Abraham JM, Reid BJ. Microsatellite instability occurs frequently and in both diploid and aneuploid cell populations of Barrett's-associated esophageal adenocarcinomas. Cancer Res. 1994; 54:3379-3382.

34. Togawa K, Jaskiewicz K, Takahashi H, Meltzer SJ, Rustgi AK. Human papillomavirus DNA sequences in esophageal squamous cell carcinoma. Gastroenterol. 1994; 107:128-136.

35. Huang Y, Yin J, Meltzer SJ. A unique p53 intragenic deletion flanked by short direct repeats results in loss of mRNA expression in human esophageal carcinoma. Carcinogenesis 1994; 8:1653-1655.

36. Suzuki H, Harpaz N, Tarmin Y, Yin J, Jiang H-Y, Bell JD, Hontanosas M, Groisman GM, Abraham JM, Meltzer SJ. Microsatellite instability in ulcerative colitis-associated colorectal dysplasias and cancers. Cancer Res. 1994; 54:4841-4844.

37. Harpaz N, Peck AL, Yin J, Fiel I, Hontanosas M, Tong TR, Laurin JN, Abraham JM, Greenwald BD, Meltzer SJ. p53 protein expression in ulcerative colitis-associated colorectal dysplasia and carcinoma. Human Pathol. 1994; 25:1069-1074.

38. Powell S, Papadopoulos N, Kinzler KW, Smolinski K, Meltzer SJ. Truncating APC gene mutations in the mutation cluster region are rare in esophageal cancers. Gastroenterol. 1994; 107:1759-1763.

39. Zhou X, Tarmin L, Yin J, Jiang H-Y, Suzuki H, Rhyu M-G, Abraham JM, Meltzer SJ. The MTS1 gene is frequently mutated in primary human esophageal tumors. Oncogene 1994; 9:3737-3741.

40. Tarmin L, Yin J, Zhou X, Suzuki H, Jiang H-Y, Abraham JM, Krasna MJ, Cottrell J, Meltzer SJ. Frequent loss of heterozygosity on chromosome 9 in adenocarcinoma and squamous cell carcinoma of the esophagus. Cancer Res. 1994; 54:6094-6096.

41. Tarmin L, Yin J, Harpaz N, Kozam M, Noordzij J, Antonio L, Jiang H-Y, Cymes K, Chan O, Meltzer SJ. APC gene mutations in ulcerative colitis-associated dysplasias and cancers versus sporadic colon neoplasms. Cancer Res. 1995; 55:2035-2038.

42. Balcer-Kubiczek EK, Yin J, Lin K, Harrison GH, Abraham JM, Meltzer SJ. p53 mutational status and survival of human breast cancer MCF7 cell variants after exposure to X-rays or fission neutrons. Radiation Res. 1995; 142:256-262.

43. Zhou X, Suzuki H, Shimada Y, Imamura M, Yin J, Jiang H-Y, Tarmin L, Abraham JM, Meltzer SJ. Genomic DNA and messenger RNA expression alterations of the CDKN2B and CDKN2 genes in esophageal squamous carcinoma cell lines. Genes, Chromosomes & Cancer 1995; 13:285-290.

44. Suzuki H, Zhou X, Yin J, Lei J, Jiang H-Y, Suzuki Y, Abraham JM, Chan T, Hannon GJ, Mergner WJ, Abraham JM, Meltzer SJ. Intragenic mutations of p15 and p16 in primary human esophageal cancers. Human Molec. Genet. 1995; 4:1883-1888.

45. Berg PE, Liu J, Yin J, Rhyu M-G, Frantz CN, Meltzer SJ. Microsatellite instability is infrequent in neuroblastoma. Cancer Epidemiology, Biomarkers & Prevention 1995; 4:907-909.

46. Nakagawa H, Zukerberg LR, Togawa K, Meltzer SJ, Nishihara T, Rustgi AK. Human cyclin D1 oncogene and esophageal squamous cell carcinoma. Cancer 1995; 76:541-549.

47. Abraham JM, Wang S, Suzuki H, Jiang H-Y, Rosenblum-Vos LS, Yin J, Meltzer SJ. Esophagin cDNA cloning and characterization: a tissue-specific member of the small proline-rich protein family that is not expressed in esophageal tumors. Cell Growth & Different. 1996; 7:855-860.

48. Zhou X, Suzuki H, Lei J, Cole K, Yin J, Suzuki Y, Abraham JM, Shimada Y, Imamura T, Chan JT, Hannon GJ, Meltzer SJ. Growth suppression of esophageal cancer cells by p16INK4 and p15INK4B in vitro. Cancer J. Sci. Am. 1996; 2:221-224.

49. Garrigue Antar L, Souza RF, Vellucci VF, Meltzer SJ, Reiss M. Loss of transforming growth factor  type II receptor gene expression in human esophageal cancer. Lab. Invest. 1996; 75:263 272.

50. Souza RF, Appel R, Yin J, Wang S, Smolinski KN, Abraham JM, Zou T-T, Shi Y-Q, Lei J, Cottrell J, Cymes K, Biden K, Simms L, Leggett B, Lynch PM, Frazier M, Powell SM, Harpaz N, Sugimura H, Young J, Meltzer SJ. Microsatellite instability in the insulin-like growth factor II receptor gene in gastrointestinal tumors. Nature Genet. 1996; 14:255-257.

51. Lei J, Zou T-T, Shi Y-Q, Smolinski KN, Yin J, Souza RF, Appel R, Wang S, Cymes K, Chan O, Harpaz N, Abraham JM, Meltzer SJ. Infrequent DPC4 gene mutation in esophageal cancer, gastric cancer, and ulcerative colitis-associated neoplasms. Oncogene 1996; 13:2459-2462.

52. Wilson KT, Ramanujam KS, Mobley HLT, Musselman RF, James SP, Meltzer SJ. Helicobacter pylori stimulates inducible nitric oxide synthase expression and activity in macrophages. Gastroenterol. 1996; 111:1524-1533.

53. Balcer-Kubiczek EK, Harrison GH, Zhang X-F, Shi Z-M, Abraham JM, McCready WA, Ampey III LL, Meltzer SJ, Jacobs MC, Davis CC. Rodent cell transformation and immediate early gene expression following 60-Hz magnetic field exposure. Envir. Health Perspect. 1996; 104:1188-1198.

54. Meltzer SJ, O'Doherty SP, Frantz CN, Smolinski K, Yin J, Cantor AB, Liu J, Valentine M, Brodeur GM, Berg PE. Allelic imbalance on chromosome 5q predicts long-term survival in neuroblastoma. Br. J. Cancer 1996; 74:1855-1861.

55. Souza RF, Lei J, Yin J, Appel R, Zou T-T, Zhou X, Wang S, Rhyu M-G, Cymes K, Chan O, Park W-S, Krasna MJ, Greenwald BD, Cottrell J, Abraham JM, Harpaz N, Meltzer SJ. A transforming growth factor-1 receptor type II mutation occurs in ulcerative colitis-associated and sporadic colorectal neoplasms. Gastroenterol. 1997; 112:40-45.

56. Simms LA, Zou T-T, Young J, Shi Y-Q, Lei J, Appel R, Rhyu M-G, Sugimura H, Chevenix-Trench G, Souza RF, Meltzer SJ, Leggett BA. Apparent protection from instability of repeat sequences in cancer-related genes in replication error positive gastrointestinal cancers. Oncogene 1997; 14:2613-2617.

57. Ouyang H, Shiwaku HO, Hagiwara H, Miura K, Abe T, Kato Y, Ohtani H, Shiiba K, Souza RF, Meltzer SJ, Horii A. The insulin-like growth factor II receptor gene is mutated in genetically unstable cancers of the endometrium, stomach, and colorectum. Cancer Res. 1997; 57:1851-1854.

58. Balcer-Kubiczek EK, Meltzer SJ, Han L-H, Zhang X-F, Zhong M-S, Harrison GH, Qin JT, Abraham JM. Csa-19, a radiation-responsive human gene, identified by an unbiased two-gel cDNA library screening method. Oncogene 1997; 14:3051-3058.

59. Souza RF, Yin J, Smolinski KN, Zou T-T, Wang S, Shi Y-Q, Rhyu M-G, Cottrell J, Abraham JM, Biden K, Simms L, Leggett B, Bova GS, Frank T, Powell SM, Sugimura H, Young J, Harpaz N, Shimizu K, Matsubara N, Meltzer SJ. Frequent mutation of the E2F-4 cell cycle gene in primary human gastrointestinal tumors. Cancer Res. 1997; 57:2350-53.

60. Zou T-T, Lei J, Shi Y-Q, Yin J, Wang S, Souza RF, Smolinski KN, Greenwald BD, Abraham JM, Harpaz N, Meltzer SJ. FHIT gene alterations in ulcerative colitis (UC) and esophageal cancer. Oncogene 1997; 15:101-105.

61. Wang S, Souza RF, Kong D, Yin J, Smolinski KN, Zou T-T, Young J, Flanders K, Sugimura H, Abraham JM, Meltzer SJ. Deficient transforming growth factor-1 activation and excessive insulin-like growth factor II expression in IGFII receptor-mutant tumors. Cancer Res. 1997; 57:2543-2546.

62. Kong D, Suzuki A, Zou T-T, Sakurada A, Kemp LW, Wakatsuki S, Yokoyama T, Yamakawa H, Furukawa T, Sato M, Ohuchi N, Sato S, Yin J, Wang S, Abraham JM, Souza RF, Smolinski KN, Meltzer SJ, Horii A. PTEN1 is frequently mutated in primary endometrial carcinomas. Nature Genet. 1997; 17:143-144.

63. Yin J, Kong D, Wang S, Zou T-T, Souza RF, Smolinski KN, Lynch PM, Frazier M, Hamilton SR, Sugimura H, Powell SM, Young J, Abraham JM, Meltzer SJ. Mutation of the hMSH3 and hMSH6 mismatch repair genes in genetically unstable human colorectal and gastric carcinomas. Human Mutation 1997; 10:474-478.

64. Cawley HM, Meltzer SJ,* de Benedetti VMG, Hollstein MC, Muehlbauer K-R, Liang L, Bennett WP, Souza RF, Greenwald BD, Cottrell J, Salabes A, Bartsch H, Trivers GE. Anti-p53 antibodies in Barrett’s esophagus or esophageal carcinoma patients can predate cancer diagnosis. Gastroenterol. 1998; 115:19-27. * = co-first author

65. Wilson KT, Fu S, Ramanujam KS, Meltzer SJ. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett’s esophagus and associated adenocarcinomas. Cancer Res. 1998; 58:2929-2934.

66. Dolan K, Garde J, Gosney J, Sissons M, Wright T, Kingsnorth AN, Walker SJ, Sutton R, Meltzer SJ, Field JK. Allelotype analysis of oesophageal adenocarcinoma: loss of heterozygosity occurs at multiple sites. Br. J. Cancer 1998; 78:950-957.

67. Simms LA, Radford-Smith G, Biden KG, Buttenshaw R, Cummings M, Jass JR, Young J, Meltzer SJ, Leggett BA. Reciprocal relationship between the tumor suppressors p53 and BAX in primary colorectal cancers. Oncogene 1998; 17:2003 2008.

68. Zou T, Fleisher AS, Kong D, Yin J, Souza RF, Wang S, Smolinski KN, Abraham JM, Meltzer SJ. Sequence alterations of IGFBP-3 in neoplastic and normal gastrointestinal tissues. Cancer Res. 1998; 58:4802-4804.

69. Balcer-Kubiczek EK, Zhang XF, Han LH, Harrison GH, Davis CC, Zhou XJ, Ioffe V, McCready WA, Abraham JM, Meltzer SJ. BIGEL analysis of gene expression in HL60 cells exposed to X rays or 60 Hz magnetic fields. Radiation Res. 1998; 150:663-672.

70. Dunn J, Garde J, Dolan K, Gosney JR, Sutton R, Meltzer SJ, Field JK. Multiple target sites of allelic imbalance on chromosome 17 in Barrett’s oesophageal cancer. Oncogene 1999; 18:987-994.

71. Biden K, Simms L, Cummings M, Buttenshaw R, Schoch E, Searle J, Gobe G, Jass J, Meltzer SJ, Leggett BA, Young J. Expression of Bcl 2 protein is decreased in colorectal adenocarcinomas with microsatellite instability. Oncogene 1999; 18:1245 1249.

72. Fleisher AS, Esteller M, Wang S, Tamura G, Suzuki H, Yin Y, Zou T-T, Abraham JM, Kong D, Smolinski KN, Shi Y-Q, Rhyu M-G, Powell SM, James SP, Wilson KT, Herman JG, Meltzer SJ. Hypermethylation of the hMLH1 gene promoter in human gastric cancers with microsatellite instability. Cancer Res. 1999; 59:1090-1095.

73. Fu S, Ramanujam KS, Wong A, Fantry GT, Drachenberg CB, James SP, Meltzer SJ, Wilson KT. Increased expression and cellular localization of inducible nitric oxide synthase and cycloxygenase-2 in Helicobacter pylori gastritis. Gastroenterol. 1999; 116:1319-1329.

74. Yin J, Harpaz N, Souza RF, Zou T, Kong D, Wang S, Leytin AL, Medalie NS, Smolinski KN, Abraham JM, Fleisher AS, Meltzer SJ. Low prevalence of the APC I1307K sequence in patients with inflammatory bowel disease. Oncogene 1999; 18:3902-3904.

75. Jass JR, Biden KG, Cummings M, Simms LA, Walsh M, Schoch E, Meltzer SJ, Wright C, Searle J, Young J, Leggett BA. Characterization of a subtype of colorectal cancer combining features of the suppressor and mild mutator pathways. J. Clin. Pathol. 1999; 52:455-460.

76. Souza RF, Wang S, Thakar M, Grubb J, Smolinski KN, Yin J, Zou T-T, Kong D, Gable CA, Sly WS, Abraham JM, Toretsky JA, Meltzer SJ. Expression of the wild-type insulin-like growth factor II receptor gene suppresses growth and causes death in colorectal carcinoma cells. Oncogene 1999; 18:4063-4068.

77. Sheikh MS, Huang Y, Fernandez-Salas EA, El-Deiry WS, Amundson S, Meltzer SJ, Yin J, Holbrook NJ, Fornace AJ. The antiapoptotic decoy receptor TRID/TRAIL-R3 is a p53-regulated DNA damage-inducible gene and is overexpressed in primary tumors of the gastrointestinal tract. Oncogene 1999; 18:4153 4159.

78. Krasna MJ, Mao YS, Sonett JR, Tamura G, Jones R, Suntharalingam M, Meltzer SJ. p53 gene protein expression predicts response and survival in esophageal cancer patients treated by trimodality therapy. Ann. Thorac. Surg. 1999; 68:2021-2025.

79. Simms LA, Young J, Wicking C, Meltzer SJ, Jass JR, Leggett BA. The apoptotic regulatory gene, BCL10, is mutated in sporadic mismatch repair deficient colorectal cancers. Cell Death Diff. 2000; 7:236-237.

80. Fleisher AS, Meltzer SJ, James SP. Colon polyps in Beckwith-Wiedmann syndrome: role of imprinted genes. Gastroenterology 2000; 118:637.

81. Tamura G, Yin J, Wang S, Fleisher AS, Zou T, Abraham JM, Kong D, Smolinski KN, Wilson KT, James SP, Silverberg SG, Nishizuka S, Motoyama T, Meltzer SJ. E-cadherin gene promoter hypermethylation in primary gastric carcinomas. J. Natl. Cancer Inst. 2000; 92:569-573.

82. Tsuchiya T, Tamura G, Sato K, Endoh Y, Sakata K, Jin Z, Motoyama T, Usuba O, Kimura W, Nishizuka S, Yin J, Fleisher AS, Zou T, Kong D, Meltzer SJ. Distinct methylation patterns of two APC gene promoters in normal and cancerous gastric epithelium. Oncogene 2000; 19:3642-6.

83. Esteller, M, Sparks, A, Toyota, M, Sanchez-Cespedes, M, Capella, G, Peinado, MA, Gonzalez, S, Tarafa, G, Sidransky, D, Meltzer, SJ, Baylin, SB, Herman, JG. Analysis of Adenomatous Polyposis Coli promoter hypermethylation in human cancer. Cancer Res. 2000; 60:4366-4371.

84. Fleisher AS, Esteller M, Leytin A, Harpaz N, Rashid A, Xu Y, Liang J, Stine OC, Yin J, Zou T-T, Abraham JM, Kong D, Wilson KT, James SP, Herman JG, Meltzer SJ. Microsatellite instability in IBD-associated neoplastic lesions is associated with hypermethylation and diminished expression of the DNA mismatch repair gene, hMLH1. Cancer Res. 2000; 60:4864-4868.

85. Kawakami, K., Brabender, J., Lord, R.V., Groshen, S., Greenwald, B.D., Krasna, M.J., Yin, J., Fleisher, A.S., Abraham, J.M., Beer, D.G., Sidransky, D., Huss, H.T., DeMeester, T.R., Eads, C.A., Laird, P.W., Ilson, D.H., Kelsen, D.P., Harpole, D., Moore, M.-B., Danenberg, K.D., Danenberg, P.V., Meltzer S.J. Hypermethylated APC promoter DNA in serum and prognosis in esophageal adenocarcinoma patients. J. Natl. Cancer Inst. 2000; 92:1805-1811.

86. Fleisher AS, Esteller M, Tamura G, Rashid A, Stine OC, Yin J, Zou TT, Abraham JM, Kong D, Nishizuka S, James SP, Wilson KT, Herman JG, Meltzer SJ. Hypermethylation of the hMLH1 gene promoter is associated with microsatellite instability in early human gastric neoplasia. Oncogene 2001; 20:329-335.

87. Akhtar M, Cheng Y, Magno RM, Ashktorab H, Smoot DT, Meltzer SJ, Wilson KT. Promoter methylation regulates Helicobacter pylori-stimulated cyclooxygenase-2 expression in gastric epithelial cells. Cancer Res. 2001; 61:2399-2403.

88. Esteller M, Cordon-Cardo C, Corn PG, Meltzer SJ, Pohar KS, Watkins NG, Capella G, Peinado MA, Matias-Guiu X, Prat J, Baylin SB, Herman JG. p14 (ARF) silencing by promoter hypermethylation mediates abnormal intracellular localization of MDM2. Cancer Res. 2001; 61:2816-2821.

89. Mori Y, Yin J, Rashid A, Leggett BA, Young J, Kuehl PM, Langenberg P, Meltzer SJ,* Stine OC. Instabilotyping: comprehensive identification of novel cancer-related genes by large-scale probing for mutations in coding region microsatellites. Cancer Res. 2001; 61:6046-6049. * = corresp. author

90. Brabender J, Usadel H, Danenberg KD, Metzger R, Schneider PM, Lord RV, Wickramasinghe K, Lum CE, Park JM, Salonga D, Sidransky D, Hölscher AH, Meltzer SJ, Danenberg PV. Adenomatous Polyposis Coli gene promoter hypermethylation in non-small cell lung cancer is associated with survival. Oncogene 2001; 20:3528-3532.

91. Trojan J, Plotz G, Brieger A, Raedle J, Meltzer SJ, Wolter M, Zeuzem S. Activation of a cryptic splicing site of PTEN and allelic imbalance in benign skin lesions in Cowden disease. J. Invest. Dermatol. 2001; 117:1650-1653.

92. Takashima H, Matsumoto Y, Matsubara N, Shirakawa Y, Kawashima R, Tanino M, Ito S, Isozaki H, Ouchida M, Meltzer SJ, Tanaka N, Shimizu K. Effect of naturally occurring E2F-4 alterations on transcriptional activation and proliferation in transfected cells. Lab Invest. 2001; 81:1565-1573.

93. Umansky M, Yasui W, Hallak A, Brill S, Shapira I, Halpern Z, Nibshoosh H, Rattan J, Meltzer S, Tahara E, Arber N. Proton pump inhibitors reduce cell cycle abnormalities in Barrett’s esophagus. Oncogene 2001; 20:7987-7991.

94. Toretsky JA, Zitomersky NL, Eskenazi AE, Voigt RW, Strauch ED, Sun CC, Huber R, Meltzer SJ, Schlessinger D. Glypican-3 expression in Wilms tumor and hepatoblastoma. J. Ped. Hematol./Oncol. 2001; 23:496-499.

95. Selaru F, Zou T, Shustova V, Xu Y, Yin J, Mori Y, Sato F, Wang S, Shibata D, Greenwald BD, Krasna MJ, Abraham JM, Meltzer SJ. Global gene expression profiling in Barrett’s esophagus and esophageal cancer: a comparative analysis using cDNA microarrays. Oncogene 2002; 21:475-478.

96. Sato F, Harpaz N, Shibata D, Xu Y, Yin J, Mori Y, Zou T-T, Wang S, Desai K, Leytin A, Selaru F, Abraham JM, Meltzer SJ. Hypermethylation of the p14ARF gene in ulcerative colitis-associated colorectal carcinogenesis. Cancer Res. 2002; 62:1148-1151.

97. Selaru F, Xu Y, Yin J, Zou T, Liu TC, Mori Y, Abraham JM, Sato F, Wang S, Twigg C, Olaru A, Shustova V, Leytin A, Shibata D, Harpaz N, Meltzer SJ. Artificial neural networks distinguish among subtypes of neoplastic colorectal lesions. Gastroenterol. 2002; 122:606-613.

98. Sato K, Tamura G, Tsuchiya T, Endoh Y, Sakata K, Motoyama T, Usuba O, Kimura W, Terashima M, Nishizuka S, Zou T, Meltzer SJ. Analysis of genetic and epigenetic alterations of the PTEN gene in gastric cancer. Virchows Arch. 2002; 440:160-165.

99. Smolinski KN, Abraham JM, Souza RF, Yin J, Wang S, Xu Y, Zou T-T, Kong D, Fleisher AS, Meltzer SJ. A functional promoter for the squamous differentiation marker esophagin that is activated during differentiation of cultured esophageal cells. Genomics 2002; 79:875-880.

100. Toyooka S, Toyooka KO, Harada K, Miyajima K, Makarla P, Sathyanarayan UG, Yin J, Sato F, Shivapurkar N, Meltzer SJ, Gazdar AF. Aberrant methylation of the CDH13 (H-cadherin) promoter region in colorectal cancers and adenomas. Cancer Res. 2002; 62:3382-3386.

101. Xu Y, Selaru FM, Yin J, Zou TT, Shustova V, Mori Y, Sato F, Liu TC, Olaru A, Wang S, Kimos MC, Perry K, Desai K, Greenwald BD, Krasna MJ, Shibata D, Abraham JM, Meltzer SJ. Artificial neural networks and gene filtering distinguish between global gene expression profiles of Barrett’s esophagus and esophageal cancer. Cancer Res. 2002; 62:3493-3497.

102. Zou T, Selaru F, Xu Y, Yin J, Shustova V, Mori Y, Sato F, Liu TC, Abraham JM, Meltzer SJ. Application of cDNA microarrays to generate a molecular taxonomy capable of distinguishing between colon cancer and normal colon. Oncogene 2002; 21:4855-4862.

103. Mori Y, Selaru FM, Olaru A, Perry K, Kimos MC, Tamura G, Matsubara N, Sato F, Wang S, Xu Y, Yin J, Zou T-T, Leggett B, Young J, Nukiwa T, Stine OC, Abraham JM, Shibata D, Meltzer SJ. Instabilotyping reveals novel unique mutational spectra in microsatellite-unstable gastric cancers. Cancer Res. 2002; 62:3641-3645.

104. Moriyama H, Sasamoto H, Kambara T, Matsubara N, Ikeda M, Baba S, Meltzer SJ, Lynch HT, Shimizu K, Tanaka N. E2F-4 mutation in hereditary non-polyposis colorectal cancer. J Exp Clin Cancer Res. 2002 Jun; 21(2):185-9.

105. Shibata DM, Sato F, Mori Y, Perry K, Yin J, Wang S, Xu Y, Olaru A, Selaru F, Spring K, Young J, Abraham JM, Meltzer SJ. Hypermethylation of HPP1 is associated with hMLH1 hypermethylation in gastric adenocarcinomas. Cancer Res. 2002 Oct 15; 62(20):5637-40.

106. Whitehall VLJ, Wynter CVA, Walsh MD, Simms LA, Purdie D, Pandeya N, Young J, Meltzer SJ, Leggett BA, Jass JR. Morphological and molecular heterogeneity within non-microsatellite instability-high colorectal cancer. Cancer Res. 2002 Nov 1; 62(21):6011-6014.

107. Sato F, Shibata D, Harpaz N, Xu Y, Yin J, Mori Y, Wang S, Olaru A, Deacu E, Selaru F, Kimos M, Hytiroglou P, Young J, Leggett B, Gazdar AF, Toyooka S, Abraham JM, Meltzer SJ. Aberrant methylation of the HPP1 gene in ulcerative colitis-associated colorectal carcinoma. Cancer Res. 2002 Dec 1; 62(23):6820-6822.

108. Yamashita K, Upadhyay S, Osada M, Hoque MO, Xiao Y, Mori M, Sato F, Meltzer SJ, Sidransky D. Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell 2002, Dec; 2(12):485-495.

109. Wang S, Mori Y, Sato F, Yin J, Xu Y, Zou TT, Olaru A, Kimos MC, Perry K, Selaru FM, Deacu E, Sun M, Shi YC, Shibata D, Abraham JM, Greenwald BD, Meltzer SJ. An LOH and mutational investigation of the ST7 gene locus in human esophageal carcinoma. Oncogene 2003 Jan 23; 22(3):467-470.

110. Mori Y, Selaru F, Sato F, Xu Y, Wang S, Yin J, Abraham JM, Olaru A, Deacu E, Kimos M, Perry K, Shibata D, Young J, Leggett B, Meltzer SJ. The impact of microsatellite instability on the molecular phenotype of colorectal tumors. Cancer Res. 2003 Aug 1; 63(15):4577-4582.

111. Olaru A, Mori Y, Yin J, Wang S, Kimos MC, Perry K, Xu Y, Sato F, Selaru FM, Deacu E, Shibata D, Abraham JM, Meltzer SJ. An LOH and mutational analysis of the ACTRII gene locus in human colorectal tumors. Lab. Invest. 2003 Dec; 83(12):1867-1861.

112. Selaru FM, Yin J, Xu Y, Epstein S, Sato F, Mori Y, Olaru A, Deacu E, Wang S, Sterian A, Fulton A, Abraham JM, Shibata D, Baquet C, Stass SA, Meltzer SJ. An unsupervised approach to identify molecular phenotypic components influencing breast cancer features. Cancer Res. 2004 Mar 1; 64(5):1584-1588.

113. Mori Y, Yin J, Sato F, Sterian A, Simms LA, Selaru FM, Xu Y, Olaru A, Wang S, Deacu E, Abraham JM, Young J, Leggett BA, Meltzer SJ. Identification of genes uniquely involved in MSI-H colon carcinogenesis by expression profiling combined with epigenetic scanning. Cancer Res. 2004 Apr 1; 64(7):2434-2438.

114. Brabender J, Marjoram P, Salonga D, Metzger R, Schneider PM, Park JM, Schneider S, Holscher AH, Danenberg KD, Yin J, Meltzer SJ, Danenberg PV, Lord RV. A multigene expression panel for the molecular diagnosis of Barrett’s esophagus and Barrett’s adenocarcinoma of the esophagus. Oncogene 2004 Jun 10; 23(27):4780-4788.

115. Stokes NR, Zhou X, Meltzer SJ, Kaper JB. Transcriptional responses of intestinal epithelial cells to infection with Vibrio cholerae. Infect Immun. 2004 Jul; 72(7):4240-4248.

116. Ma X, Yang Q, Wilson KT, Kundu N, Meltzer SJ, Fulton AM. Promoter methylation regulates cyclooxygenase (COX-2) expression in human and murine breast cancer. Breast Cancer Res. 2004; 6(4):R316-321.

117. Schulmann K, Yin J, Sterian A, Xu T, Sato F, Bryant L, Mori Y, Olaru A, Deacu E, Wang S, Brenner DE, Krasna MJ, Abraham JM, Baron JA, Greenwald BD, Meltzer SJ. Methylation profiling for the prediction of Barrett’s esophagus progression. Gastroenterol. 2004 Jul; 127(1):331.

118. Kimos MC, Borkowski A, Wang LD, Yang CS, Perry K, Olaru A, Sisodia L, Selaru FM, Mori Y, Xu Y, Yin J, Wang S, Abraham JM, Meltzer SJ. Esophagin and proliferating cell nuclear antigen (PCNA) as biomarkers of human esophageal epithelial differentiation and proliferation in carcinogenesis. Int. J. Cancer 2004 Sep 1; 111(3):415-417.

119. Deacu E, Mori Y, Sato F, Yin J, Olaru A, Sterian A, Xu Y, Wang S, Schulmann K, Bryant L, Kan T, Abraham JM, Meltzer SJ. Activin type II receptor restoration in ACVR2-deficient colon cancer cells induces TGF-beta response pathway genes. Cancer Res. 2004 Nov 1; 64(21):7690-7696.

120. Kan T, Shimada Y, Sato F, Ito T, Kondo K, Watanabe G, Maeda M, Yamasaki S, Meltzer SJ, Imamura M. Prediction of lymph node metastasis with use of artificial neural networks based on gene expression profiles in esophageal squamous cell carcinoma. Ann. Surg. Oncol. 2004 Dec; 11(12):1070-1078.

121. Xu H, Chatuvedi R, Cheng Y, Bussiere FI, Asim M, Yao MD, Potosky D, Meltzer SJ, Rhee JG, Kim SS, Moss SF, Hacker A, Wang Y, Casero RA, Wilson KT. Spermine oxidation by Helicobacter pylori results in apoptosis and DNA damage: Implications for gastric carcinogenesis. Cancer Res. 2004 Dec. 1; 64(23):8521-8525.

122. Schulmann K, Brasch FE, Kunstmann E, Engel C, Pagenstecher C, Vogelsang H, Kruger S, Vogel T, Knaebel HP, Ruschoff J, Hahn SA, Knebel-Doeberitz MV, Moeslein G, Meltzer SJ, Schackert HK, Tympner C, Mangold E, Schmiegel W. HNPCC-associated small bowel cancer: Clinical and molecular characteristics. Gastroenterol. 2005 Mar; 128(3):590-599.

123. Sato F, Shimada Y, Selaru FM Maeda M, Shibata D, Watanabe G, Mori Y, Stass SA, Imamura M, Meltzer SJ. Prediction of survival in esophageal cancer using artificial neural networks. Cancer 2005 Apr 15; 103(8):1596-1605.

124. Takahashi T, Suzuki M, Shigematsu H, Shivapurkar N, Echebiri C, Nomura M, Stastny V, Augustus M, Wu CW, Wistuba II, Meltzer SJ, Gazdar AF. Aberrant methylation of Reprimo in human malignancies. Int. J. Cancer 2005 Jul 1; 115(4):503-510.

125. Schulmann K, Sterian A, Berki A, Yin J, Sato F, Xu Y, Olaru A, Wang S, Mori Y, Deacu E, Hamilton J, Kan T, Krasna MJ, Beer DG, Pepe MS, Abraham JM, Feng Z, Schmiegel W, Greenwald BD, Meltzer SJ. Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk. Oncogene 2005 Jun 9; 24(25):4138-4148.

126. Schulmann K, Mori Y, Croog V, Yin J, Olaru A, Sterian A, Sato F, Wang S, Xu Y, Deacu E, Abraham JM, Schmiegel W, Harpaz N, Meltzer SJ. Molecular phenotype of inflammatory bowel disease-associated neoplasms with microsatellite instability. Gastroenterol. 2005 Jul; 129:74-85.

127. Brabender J, Marjoram P, Lord RVN, Metzger R, Salonga D, Vallbohmer D, Schafer H, Danenberg KD, Danenberg PV, Baldus SE, Holscher AH, Meltzer SJ, Schneider PM. The molecular signature of normal squamous esophagus identifies the presence of a field effect and can discriminate between patients with Barrett’s esophagus and Barrett’s-associated adenocarcinoma. Cancer Epidemiol. Biomarkers & Prev. 2005 Sep; 14(9):2113-2117.

128. Baquet CR, Commiskey P, Mack K, Meltzer SJ, Mishra SI. Esophageal cancer epidemiology in blacks and whites: racial and gender disparities in incidence, mortality, survival rates and histology. J. Natl. Med. Assoc. 2005 Nov; 97(11);1471-1478.

129. Kan T, Yamasaki S, Kondo K, Teratani N, Kawabe A, Kaganoi J, Meltzer SJ, Imamura M, Shimada Y. A new specific gene expression in squamous cell carcinoma of the esophagus detected using representational difference analysis and cDNA microarray. Oncology 2006 Jan 27; 70(1):25-33.

130. Takahashi T, Shigematsu H, Shivapurkar N, Reddy J, Zheng Y, Feng Z, Suzuki M, Nomura M, Augustus M, Yin J, Meltzer SJ, Gazdar AF. Aberrant promoter methylation of multiple genes during multistep pathogenesis of colorectal cancers. Int. J. Cancer 2006 Feb 15; 118(4):924-931.

131. Shibata D, Mori Y, Cai K, Zhang L, Yin J, Elahi A, Hamelin R, Wong YF, Lo WK, Chung TKH, Sato F, Karpeh MS, Jr., Meltzer SJ. RAB32 hypermethylation and microsatellite instability in gastric and endometrial adenocarcinomas. Int. J. Cancer 2006 Mar 23; 119:801-806.

132. Sato F, Abraham JM, Yin J, Kan T, Ito T, Mori Y, Hamilton JP, Jin Z, Cheng Y, Paun B, Berki AT, Wang S, Shimada T, Meltzer SJ. Polo-like kinase (PLK) and Survivin are Esophageal Tumor-Specific Promoters. Biochem. Biophys. Res. Commun. 2006 Apr 7; 342(2):465-471.

133. Wang S, Zhan M, Yin J, Abraham JM, Mori Y, Sato F, Xu Y, Olaru A, Li H, Schulmann K, Sterian A, Kan T, Hamilton JP, Chai K, Deacu E, Berki AT, Greenwald BD and Meltzer SJ. Transcriptional profiling suggests that Barrett's metaplasia is an advanced intermediate stage in esophageal adenocarcinoma. Oncogene 2006 Jun 1; 25(23):3346-3356.

134. Hamilton JP, Sato F, Greenwald BD, Suntharalingam M, Krasna MJ, Edelman MJ, Doyle LA, Berki AT, Abraham JM, Mori Y, Kan T, Mantzur C, Paun T, Wang S, Ito T, Jin Z, Meltzer SJ. Promoter hypermethylation and response to chemotherapy and radiation in esophageal cancer. Clin. Gastroenterol. Hepatol. 2006 Jun; 4(6):701-708.

135. Sterian A, Kan T, Mori Y, Berki A, Olaru A, Schulmann K, Sato F, Wang S, Paun B, Cai K, Hamilton JP, Abraham JM, Greenwald BD, Meltzer SJ. Mutational and deletion analyses of the chromosome 4q24-31 region in esophageal adenocarcinoma. Oncology 2006 Jul 7; 70(3):168-172.

136. O’Neill JP, Velalar CN, Lee DI, Zhang B, Nakanishi T, Tang Y, Selaru FM, Ross D, Meltzer SJ, Hussain A. Thapsigarin resistance in human prostate cancer cells. Int. J. Cancer 2006 Aug 1; 107(3):649-659.

137. Mori Y, Cai K, Cheng Y, Wang S, Paun B, Hamilton JP, Jin Z, Sato F, Berki AT, Kan T, Ito T, Mantzur C, Abraham JM, Meltzer SJ. A genome-wide search identifies epigenetic silencing of somatostatin, tachykinin-1, and five other genes in colon cancer. Gastroenterol. 2006 Sep; 131(3): 797-808.

138. Hamilton JP, Sato F, Jin Z, Greenwald BD, Ito T, Mori Y, Paun B, Kan T, Cheng Y, Wang S, Mantzur C, Abraham JM, Meltzer SJ. Reprimo methylation is a potential early biomarker of Barrett’s-associated neoplastic progression. Clin. Cancer Res. 2006 Nov 15; 12(22):6637-6642.

139. Kanner WA, Drachenberg CB, Papadimitriou JC, Wang S, Meltzer SJ, Sklar GN. Urethral stromal tumor with pacemaker cell phenotype. Ultrastruct Pathol. 2007 Jan-Feb;31(1):63-71.

140. Konishi K, Shen L, Wang S, Meltzer SJ, Issa J-PJ. Rare CpG island methylator phenotype in ulcerative colitis-associated neoplasias. Gastroenterol. 2007 Apr; 132(4):1254-1260.

141. Liu Z, Jiang F, Tian G, Wang S, Sato F, Meltzer SJ, Tan M. Sparse logistic regression with Lp penalty for biomarker identification. Statistical Applics. Genet. Molec. Biol. 2007 Feb 10; 6:Article6.

142. Jin Z, Mori Y, Yang J, Sato F, Ito T, Cheng Y, Paun B, Hamilton JP, Kan T, Olaru A, David S, Agarwal R, Abraham JM, Beer D, Montgomery E, Meltzer SJ. Hypermethylation of the nel-like 1 gene is a common and early event and is associated with a poor prognosis in early-stage esophageal adenocarcinoma. Oncogene 2007 Sep 20;26(43):6332-40.

143. Kan T, Paun B, Mori Y, Sato F, Jin Z, Hamilton JP, Ito T, Cheng Y, David S, Olaru A, Yang J, Agarwal R, Abraham JM, Meltzer SJ. Rarity of somatic mutation and frequency of normal sequence variation detected in sporadic colon adenocarcinoma using high-throughput cDNA sequencing. Bioinformatics & Biology Insights 2007; 1:1-16.

144. Abraham JM, Sato F, Cheng Y, Paun B, Ito T, Kan T, Olaru A, Jin Z, Yang J, Agarwal R, David S, Hamilton JP, Mori Y, Meltzer SJ. A Novel Decapeptide that Binds Avidly and Delivers Radioisotope to Colon Cancer Cells. PLoS ONE 2007 Oct 3;2(10):e964.

145. Jin Z, Olaru A, Yang J, Sato F, Cheng Y, Mori Y, Mantzur C, Paun B, Hamilton JP, Ito T, Kan T, Wang S, David S, Agarwal R, Beer DG, Abraham JM, Meltzer SJ. Hypermethylation of Tachykinin-1 is Associated with a Poor Prognosis in Human Esophageal Squamous Cell Carcinoma. Clin. Cancer Res. 2007 Nov 1;13(21):6293-6300.

146. Jin Z, Mori Y, Hamilton JP, Olaru A, Sato F, Yang J, Ito T, Paun B, Kan T, Agarwal R, Meltzer SJ. Hypermethylation of the somatostatin promoter is a common, early event in human esophageal carcinogenesis. Cancer 2008 Jan 1;112(1):43-49.
147. Jin Z, Hamilton JP, Yang J, Mori Y, Olaru A, Sato F, Ito T, Kan T, Cheng Y, Paun B, David S, Agarwal R, Abraham JM, Meltzer SJ. Hypermethylation of the AKAP12 Promoter is a Potential Biomarker of Barrett's-Associated Esophageal Neoplastic Progression. Cancer Epidemiology, Biomarkers & Prevention 2008 Jan; 17(1):1-16.

148. Selaru FM, Wang S, Yin J, Schulmann K, Xu Y, Yuriko Mori Y, Olaru A, Sato F, Hamilton JP, Abraham JM, Schneider P, Greenwald BD, Brabender J, Meltzer SJ. Beyond Field Effect: Analysis of Shrunken Centroids in Normal Esophageal Epithelia Detects Concomitant Esophageal Adenocarcinoma. Bioinformatics & Biology Insights, 2007; 1:127-136.

149. Ito T, Shimada Y, Kan T, David S, Abraham JM, Mori Y, Agarwal R, Cheng Y, Paun B, Jin Z, Olaru A, Hamilton JP, Yang J, Meltzer SJ, Sato F. PTTG1 promotes lymph node metastasis in esophageal squamous cell carcinoma by increasing cell motility. Cancer Research 2008 May 1;68(9):3214-3224.

150. Sato F, Jin Z, Schulmann K, Wang J, Greenwald BD, Ito T, Kan T, Hamilton JP, Yang J, Paun B, David S, Olaru A, Cheng Y, Mori Y, Abraham JM, Yfantis HG, Wu T, Fredericksen MB, Wang KK, Canto M, Romero Y, Feng Z, Meltzer SJ. Three-tiered risk stratification method to predict progression in Barrett’s esophagus using epigenetic and clinical features. PLoS ONE 2008 Apr 2; 3(4):e1890.

151. Ito T, Tanaka E, Kadowaki T, Kan T, Higashiyama M, Shiojima S, Tomoda S, Myoumoto A, Akiyama H, Nobumasa H, Matsumoto S, Miyamoto S, Mitsumori M, Sato F, Watanabe G, Itami A, Meltzer SJ, Tsujimoto G, Shimada Y. An ultrasensitive new DNA microarray chip provides gene expression profiles for preoperative esophageal cancer biopsies without RNA amplification. Oncology 2008 May 30, 73(5-6):366-375.

152. Abraham JM, Cheng Y, Hamilton JP, Paun B, Jin Z, Agarwal R, Kan T, David S, Olaru A, Yang J, Ito T, Selaru FM, Mori Y, Meltzer SJ. Generation of small 32P-labeled peptides as a potential approach to colorectal cancer therapy. PLoS ONE 2008 Jun 25; 3(6):e2508.

153. Jin Z, Hamilton JP, Yang J, Mori Y, Olaru A, Sato F, Ito T, Kan T, Cheng Y, Paun B, David S, Agarwal R, Abraham JM, Meltzer SJ. Promoter hypermethylation of CDH13 is a common, early event in human esophageal adenocarcinogenesis and correlates with clinical risk factors. Int. J. Cancer 2008 Nov 15;123(10):2331-2336.

154. Selaru FM, Olaru AV, Kan T, David S, Cheng Y, Mori Y, Yang J, Paun B, Jin Z, Agarwal R, Hamilton JP, Abraham JM, Georgiades C, Alvarez H, Vivekanandan P, Maitra A, Torbenson M, Thuluvath PJ, Gores GJ, LaRusso NF, Hruban R, Meltzer SJ. MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3. Hepatology 2009 Feb 4;49(5):1595-1601.

155. Kan T, Sato F, Ito T, Matsumura N, David S, Cheng Y, Agarwal R, Paun BC, Jin Z, Olaru AV, Selaru FM, Hamilton JP, Yang J, Abraham JM, Mori Y, Meltzer SJ. The miR-25-93-106b polycistron, activated by de novo genomic amplification, functions as an oncogene by suppressing p21 and Bim.
Gastroenterology. 2009 May;136(5):1689-700.

156. Jin Z, Cheng Y, Zheng Y, Gu J, Sato F, Olaru AV, Paun B, Yang J, Kan T, Ito T, Hamilton JP, Selaru FM, Mori Y, Agarwal R, David S, Abraham JM, Wolfsen H, Shaheen NJ, Wang J, Canto M, Washington K, Romero Y, Wang KK, Feng Z, Sampliner RD, Meltzer SJ. A multi-center, double-blinded validation study of methylation biomarkers for progression prediction in Barrett’s esophagus. Cancer Res. 2009, in press.



                                              Last modified 05/12/2009  

  © Copyright 2006-2007 JHU GI Biomarker Lab. All Rights Reserved.        Johns Hopkins University